Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Sep;156(3):437-44.
doi: 10.1016/j.ahj.2008.05.003. Epub 2008 Jul 7.

Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure

Wei Jiang  1 , Christopher O'Connor, Susan G Silva, Maragatha Kuchibhatla, Michael S Cuffe, Dwayne D Callwood, Bosh Zakhary, Elizabeth Henke, Rebekka M Arias, Ranga Krishnan; SADHART-CHF Investigators
Affiliations
Randomized Controlled Trial

Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure

Wei Jiang et al. Am Heart J. 2008 Sep.

Abstract

Background: Sertraline, a selective serotonin-reuptake inhibitor, has demonstrated substantial mood improvement in patients with post myocardial infarction or with unstable angina. The impact of sertraline on the prognosis and depression of patients with chronic heart failure (HF) and comorbid major depressive disorder (MDD) is unknown.

Method: This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of sertraline in the treatment of MDD in patients with HF. The study is designed also to examine the effects of treating depression on cardiac events and morbidity/mortality in patients with HF. Approximately 500 men and women who are >or=45 years of age with current MDD and chronic systolic HF, characterized by left ventricular ejection fraction <or=45% and New York Heart Association class >or=II, comprise the study population. Eligible participants are randomized to either sertraline or placebo for a 12-week acute treatment phase. All patients, regardless of acute treatment phase completion, are followed routinely until the last subject completes 6-month follow-up. Quality of life and certain physiologic parameters, as well as pro-inflammatory and HF biomarkers, that may reflect the impact of sertraline in this particular population are measured at baseline and at the end of the acute treatment phase.

Conclusion: Because of the high prevalence of depression and its significant adverse impact on prognosis of patients with ischemic heart disease (IHD) and HF, the Safety and Efficacy of Sertraline for Depression in Patients with Chronic Heart Failure (SADHART-CHF) trial aims to assess the effects of sertraline on response of depression as well as on the cardiac prognosis of patients with HF.

Trial registration: ClinicalTrials.gov NCT00078286.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of SADHART-CHF trial
See this image and copyright information in PMC

References

    1. Gradman A, Deedwania P, Cody R. Predictors of total mortality and sudden death in mild to moderate heart failure. JACC. 1989;14:564. - PubMed
    1. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol. 1988;62:25A. - PubMed
    1. Braunwald E. Heart disease: a textbook of cardiovascular medicine. 4th edition. Vol. 11 W.B. Saunders Company; 1992.
    1. Sziachic J. Correlates and prognostic implications of exercise capacity in chronic congestive heart failure. Am J Cardiol. 1986;55:1037. - PubMed
    1. Packer M, Gottieb SS, Blum MA. Immediate and long-term pathophysiologic mechanisms underlying the genesis of sudden cardiac death in patients with CHF. Am J Med. 1987;82 suppl. 3a:4. - PubMed

Publication types

MeSH terms

Associated data